Overview

Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis

Status:
Terminated

Trial end date:
2014-03-01

Target enrollment:

Participant gender:

Summary

This is an investigator sponsored double-blinded, multinational, multi center, randomized (2:1 active:placebo), placebo-controlled, phase IIa trial in severe pneumonia patients with severe sepsis or septic shock, investigating the safety and efficacy of co-administration of Iloprost and escalating doses of Eptifibatide for continuous intravenous infusion in totally 36 patients.

Phase:

Phase 2

Details

Lead Sponsor:

Thrombologic ApS

Collaborators:

Anders Perner
Rigshospitalet, Denmark

Treatments:

Calcium heparin
Dalteparin
Eptifibatide
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin